真实世界证据（RWE）解决方案市场：依组件（资料集、服务）、应用（药物研发、市场准入、上市后监测）、最终用户（製药和生物技术公司、支付方、医疗服务提供者）和地区划分 - 全球预测（～2036年）

全球真实世界证据解决方案市场预计在预测期（2026-2036年）内将以 12.2%的年复合成长率成长，从2026年的39亿美元成长到2036年的约 89亿美元。

本报告对全球五大主要地区的真实世界证据解决方案市场进行了详细分析，重点关注当前市场趋势、市场规模、近期发展以及至2036年的预测。基于广泛的二级和一级研究以及对市场现状的详细分析，本报告对关键产业驱动因素、限制因素、机会和挑战的影响进行了分析。

推动真实世界证据解决方案市场成长的关键因素包括慢性病发病率上升、对个人化医疗的日益重视、全球向价值医疗模式的转变，以及药物研发和商业化过程中对真实世界证据的日益广泛应用。此外，医疗系统的快速数位化、人工智慧和机器学习等先进技术的整合、监管机构对真实世界证据在决策中的认可，以及证据生成日益复杂化，预计都将为真实世界证据解决方案市场的企业创造巨大的成长机会。

主要市场趋势

人工智慧在进阶分析中的应用：影响真实世界证据解决方案市场的关键趋势之一是将人工智慧（AI）和机器学习深度整合到分析平台中。人工智慧演算法可以处理大量、复杂的资料集，识别模式，预测结果，并产生仅靠人工分析无法实现的假设。自然语言处理技术能够分析非结构化的临床记录，而机器学习演算法可以从庞大的电子健康记录（EHR）资料库中识别临床试验患者，并建立疾病进展的预测模型。这一趋势正推动市场从描述性分析转向预测性和规范性分析，从真实世界资料中释放新的价值。

日益关注端到端真实世界证据（RWE）服务和策略合作伙伴关係：另一个关键趋势是对涵盖整个证据产生生命週期（从研究设计和资料收集到分析和报告）的全面、端到端 RWE 服务的需求不断成长。生命科学公司越来越倾向于寻求能够提供全面解决方案而非零散的、基于专案的服务的策略合作伙伴。这推动了行业整合，大型资料分析公司收购专业的RWE 公司并建立整合能力。端到端服务提供者提供整合平台和深厚的治疗领域专业知识，使客户能够将 RWE 生成融入其核心运营，从早期研发到商业化和上市后活动。

监管机构的认可和新兴指南：包括 FDA 和 EMA 在内的监管机构已製定明确的路径和指南，将 RWE 纳入其决策流程，这大幅促进了对 RWE 解决方案的信任和投资。监管政策的明朗化加速整个产业的采用，并为证据的生成和利用创造新的机会。

市场区隔

依组成部分

依组成部分划分，预计到2026年，资料集部分将占据整个真实世界证据解决方案市场的最大占有率。这一主导地位主要归功于高品质、经过整理的资料的重要性，而这正是任何真实世界证据研究的基础。资料集部分包含多种资料来源，包括电子病历（EMR）、电子健康记录（EHR）、理赔资料、病患登记资料和多源资料集。这些资料集的价值在于其规模、纵向特性以及能够分析患者随时间推移的就医历程。能够有效连接和整合不同资料集以建立全面患者檔案的资料提供者在市场中具有优势。来自不同医疗机构的真实世界资料日益丰富，以及对资料品质和标准化的日益重视，推动对精选资料集的持续需求。

然而，预计在预测期内，咨询和分析领域的年复合成长率将最高。随着真实世界资料的数量和复杂性持续呈指数级成长，对专业知识和先进分析工具的需求也变得越来越重要，这些工具能够帮助企业从中获得有意义的洞见。该领域涵盖研究设计、生物统计学、流行病学和卫生经济学的服务，以及利用人工智慧（AI）和机器学习的先进分析平台。对方法有效、符合规范且能够产生可靠、可操作洞见的真实世界证据（RWE）研究的需求，推动咨询和分析服务的成长。各组织越来越意识到，仅仅拥有资料是不够的；需要专家指导才能将原始资料转化为策略性商业智慧。

依应用领域划分

依应用领域划分，预计到2026年，市场准入和偿付/覆盖决策领域将占据整个真实世界证据解决方案市场的最大占有率。该领域的领先地位反映了在当今成本受限的医疗保健环境下，向支付方证明产品价值的重要性。支付方越来越需要强而有力的证据来支持新产品的真实世界价值，然后再做出有利的偿付决定。真实世界证据（RWE）用于建立经济模型、进行比较疗效研究，并证明产品对患者预后和医疗资源利用的影响。这些证据对于製造商进行价格谈判、获得药品目录收录以及实现市场准入目标非常重要。

药物研发和审批是另一个关键应用领域，预计在预测期内将快速成长。真实世界证据正被策略性地用于最佳化临床试验设计、加速患者招募，并在某些情况下作为临床试验的外部或合成对照组，尤其是在罕见疾病和肿瘤领域。包括FDA和EMA在内的监管机构正日益接受真实世界证据（RWE）用于标籤扩展和新产品审批，这是该领域成长的关键驱动因素。上市后监测正成为一个新的应用领域，製造商日益利用RWE在产品上市后监测产品的安全性、有效性和真实世界表现。

依最终使用者划分

依最终用户划分，预计到2026年，製药、生技和医疗器材产业将占据最大的市场占有率。这些机构是RWE解决方案的主要用户，并在产品生命週期的各个阶段（从早期开发到商业化和上市后活动）都加以利用。支付者和医疗服务提供者是一个重要且快速成长的最终用户群体，他们越来越依赖RWE来最佳化医疗覆盖决策、临床方案和医疗服务策略。在这些不同的终端使用者类别中，RWE（真实世界证据）融入医疗保健决策流程推动市场持续扩张。

区域分析

对该产业的详细区域分析提供了对五大主要区域（北美、欧洲、亚太、拉丁美洲以及中东和非洲）及其主要国家的深入定性和定量见解。北美将继续保持领先地位，在2026年占据全球真实世界证据解决方案市场最大的市场占有率。这一优势主要归功于其高度发达的医疗保健基础设施、数位健康技术的广泛应用以及FDA制定的清晰的RWE监管框架。北美拥有许多世界领先的RWE公司和庞大的製药产业，而製药业正是这些解决方案的主要消费者。此外，北美拥有先进的支付方环境，强调实证决策。对健康资讯科技和巨量资料分析的大量投资进一步巩固了该地区的领先地位。

欧洲拥有全球第二大真实世界证据解决方案市场，这主要得益于各国政府对健康资料研究的大力支持，以及诸如欧洲健康资料空间（EHDS）等目的是促进跨境安全存取健康资料的举措。儘管资料环境分散和严格的GDPR 法规带来了挑战，但循证医学倡议和监管协调为市场的持续成长提供了支撑。德国、法国和英国等国家在真实世界证据的采纳和实施方面处于领先地位。

预计亚太地区将在预测期内实现最快成长。这一加速成长的驱动因素包括医疗保健支出不断增加、中国和印度等国家医疗保健系统的快速数位化以及对生物医学研发的日益重视。随着当地监管机构在运用真实世界证据方面日益成熟，以及跨国製药公司在该地区扩大业务，对综合性真实世界证据解决方案的需求预计将显着成长。拉丁美洲以及中东和非洲地区由于医疗保健投资的成长和实证医学实践的日益普及，也呈现出新兴机会。

目录

第1章 引言

第2章 研究方法

第3章 执行摘要

• 依组件划分的市场分析
• 依应用划分的市场分析
• 依最终用户划分的市场分析
• 依地区划分的市场分析
• 竞争分析

第4章 市场洞察

• 市场驱动因素
  • 日益关注个人化医疗与价值医疗
  • 药物研发成本上升与延误
  • 监管机构对真实世界证据（RWE）的接受度不断提高
• 市场限制因素
  • 资料隐私与安全关注点
  • 缺乏标准化的研究方法
• 市场机会
  • 新兴经济体
  • 日益关注端到端真实世界资料（RWE）服务
• 市场挑战
  • 资料品质与完整性问题
• 市场趋势
  • 人工智慧的整合
  • 药物研发和商业化中 RWE 的应用日益广泛
• 波特五力分析

第5章 全球真实世界证据解决方案市场（依组件划分）

• 资料集
  • 分散式资料集
    • 电子病历（EMR）、电子健康记录（EHR）和临床资料
    • 计费和计费资料
    • 药局资料
    • 产品与疾病登记资料
    • 基因组资料
    • 其他分散式资料集
  • 整合资料集
• 咨询与分析

第6章 全球真实世界证据解决方案市场（依应用领域划分）

• 市场准入与偿付/承保决策
• 药物研发与核准
  • 肿瘤学
  • 神经病学
  • 免疫学
  • 心血管疾病
  • 其他治疗领域
• 上市后监测
• 医疗器材研发与审批
• 其他应用

第7章 全球真实世界证据解决方案市场（依最终用户划分）

• 製药公司、生技公司及医疗器材製造商
• 医疗支付方
• 医疗服务提供方
• 其他最终用户

第8章 真实世界证据解决方案市场：依地区

• 北美
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 亚太其他地区
• 拉丁美洲
• 中东和非洲

第9章 竞争格局

• 关键成长策略
• 竞争概览
• 主要公司市场占有率/排名

第10章 公司简介

• IQVIA Holdings Inc.
• Icon plc
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Oracle Corporation
• Elevance Health, Inc.
• Clinigen Group Plc
• Cognizant Technology Solutions Corporation
• Revvity, Inc.
• SAS Institute Inc.
• Parexel International Corporation
• Healthverity, Inc.

第11章 附录

According to the research report titled, 'Real-World Evidence (RWE) Solutions Market by Component (Datasets, Services), Application (Drug Development, Market Access, Post-Market Surveillance), End User (Pharma & Biotech, Payers, Providers), and Geography - Global Forecast to 2036,' the global real-world evidence solutions market is expected to reach approximately USD 8.9 billion by 2036 from USD 3.9 billion in 2026, at a CAGR of 12.2% during the forecast period (2026-2036).

The report provides an in-depth analysis of the global real-world evidence solutions market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036. Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges.

The major factors driving the growth of the real-world evidence solutions market include the rising incidence of chronic diseases, increasing focus on personalized healthcare, a global shift toward value-based care, and the growing adoption of RWE in drug development and commercialization. Additionally, the rapid digitalization of healthcare systems, integration of advanced technologies like artificial intelligence and machine learning, regulatory acceptance of RWE for decision-making, and the rising complexity of evidence generation are expected to create significant growth opportunities for players operating in the real-world evidence solutions market.

Key Market Trends

Integration of Artificial Intelligence for Advanced Analytics: A key trend shaping the RWE solutions market is the deep integration of artificial intelligence and machine learning into analytics platforms. AI algorithms can process massive, complex datasets to identify patterns, predict outcomes, and generate hypotheses that would be impossible for human analysis alone. Natural language processing enables analysis of unstructured clinical notes, while machine learning algorithms identify eligible patients for trials from large EHR databases and create predictive models for disease progression. This trend is transitioning the market from descriptive analytics toward predictive and prescriptive analytics, unlocking new levels of value from real-world data.

Rising Focus on End-to-End RWE Services and Strategic Partnerships: Another major trend is the growing demand for comprehensive end-to-end RWE services spanning the entire evidence generation lifecycle, from study design and data sourcing through analysis and reporting. Life sciences companies are increasingly seeking strategic partners who can provide holistic solutions rather than fragmented, project-based services. This has led to consolidation activity, with larger data and analytics players acquiring specialized RWE firms to build integrated capabilities. End-to-end providers offer integrated platforms and deep therapeutic area expertise, enabling clients to embed RWE generation into core operations from early research and development through commercialization and post-market activities.

Regulatory Acceptance and Guidance Development: Regulatory bodies including the FDA and EMA have established clear pathways and guidance for incorporating RWE into decision-making processes, significantly boosting confidence and investment in RWE solutions. This regulatory clarity is accelerating adoption across the industry and creating new opportunities for evidence generation and utilization.

Market Segmentation

Based on Component

By component, the Datasets segment is expected to account for the largest share of the overall real-world evidence solutions market in 2026. This dominance is primarily attributed to the fundamental importance of high-quality, curated data as the raw material for any RWE study. The datasets segment comprises diverse data sources including electronic medical records (EMR), electronic health records (EHR), claims data, patient registries, and integrated datasets that combine multiple sources. The value of these datasets lies in their scale, longitudinal nature, and ability to enable analysis of patient journeys over extended periods. Data providers who can successfully link and integrate disparate datasets to create comprehensive patient profiles command premium positioning in the market. The increasing availability of real-world data from diverse healthcare settings and the growing emphasis on data quality and standardization are driving sustained demand for curated datasets.

However, the Consulting & Analytics segment is expected to grow at the fastest CAGR during the forecast period. As the volume and complexity of real-world data continue to expand exponentially, the demand for specialized expertise and advanced analytical tools to derive meaningful insights becomes increasingly critical. This segment encompasses services for study design, biostatistics, epidemiology, health economics, and access to advanced analytics platforms powered by artificial intelligence and machine learning. The requirement for methodologically sound, regulatory-grade RWE studies that generate credible, actionable insights is driving accelerated growth in consulting and analytics services. Organizations are increasingly recognizing that data alone is insufficient; they require expert guidance to transform raw data into strategic business intelligence.

Based on Application

By application, the Market Access & Reimbursement/Coverage Decisions segment is expected to hold the largest share of the overall real-world evidence solutions market in 2026. This segment's dominance reflects the critical importance of demonstrating product value to healthcare payers in today's cost-constrained healthcare environment. Payers are increasingly demanding robust evidence of a new product's real-world value before granting favorable reimbursement decisions. RWE is utilized to develop economic models, conduct comparative effectiveness research, and demonstrate how products impact patient outcomes and healthcare resource utilization. This evidence is essential for manufacturers to negotiate pricing, secure formulary placement, and achieve market access objectives.

The Drug Development & Approvals segment represents another major application area and is expected to grow at a rapid pace during the forecast period. Real-world evidence is being strategically leveraged to optimize clinical trial design, accelerate patient recruitment, and in certain cases, serve as external or synthetic control arms for clinical trials, particularly in rare diseases and oncology. The regulatory acceptance of RWE for label expansions and even initial product approvals by agencies including the FDA and EMA represents a major catalyst driving growth in this segment. Post-Market Surveillance represents an emerging application area as manufacturers increasingly utilize RWE to monitor product safety, effectiveness, and real-world performance following market launch.

Based on End User

By end user, the Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to hold the largest share of the market in 2026. These organizations are major consumers of RWE solutions, utilizing them throughout the product lifecycle from early development through commercialization and post-market activities. Payers and Healthcare Providers represent significant and growing end-user segments as they increasingly rely on RWE to optimize coverage decisions, clinical protocols, and care delivery strategies. The integration of RWE into healthcare decision-making processes across these diverse end-user categories is driving sustained market expansion.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. In 2026, North America dominates the global real-world evidence solutions market with the largest market share. This dominance is primarily attributed to the presence of a well-developed healthcare infrastructure, high adoption of digital health technologies, and a clear regulatory framework for RWE established by the FDA. North America is home to many of the world's leading RWE companies, a large pharmaceutical industry that represents a major consumer of these solutions, and a sophisticated payer landscape that heavily relies on evidence-based decision-making. The significant investment in healthcare information technology and big data analytics further solidifies the region's leading position.

Europe represents the second-largest market for real-world evidence solutions, driven by strong government support for health data research and initiatives like the European Health Data Space (EHDS), which aims to facilitate secure, cross-border access to health data. While navigating the fragmented data landscape and strict GDPR regulations presents challenges, the commitment to evidence-based healthcare and regulatory harmonization supports sustained market growth. Countries including Germany, France, and the United Kingdom are at the forefront of RWE adoption and implementation.

Asia-Pacific is projected to be the fastest-growing region during the forecast period. This accelerated growth is fueled by rising healthcare expenditure, rapid digitalization of healthcare systems in countries including China and India, and a growing focus on biomedical research and development. As local regulatory bodies become more sophisticated in their utilization of RWE, and as multinational pharmaceutical companies expand their operations across the region, the demand for comprehensive RWE solutions is expected to accelerate significantly. Latin America and the Middle East & Africa represent emerging market opportunities with growing healthcare investments and increasing adoption of evidence-based healthcare practices.

Key Players

The key players operating in the global real-world evidence solutions market are IQVIA Holdings Inc., Icon plc, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Oracle Corporation, Elevance Health, Inc., Clinigen Group Plc, Cognizant Technology Solutions Corporation, Revvity, Inc., SAS Institute Inc., Parexel International Corporation, and Healthverity, Inc., among others. These companies compete based on the breadth and quality of their data assets, the sophistication of their analytical platforms, their therapeutic area expertise, and their ability to provide strategic, end-to-end solutions that meet the evolving needs of the life sciences industry and healthcare payers. Market consolidation has characterized the industry, with larger players acquiring specialized RWE firms to build comprehensive capabilities and expand geographic presence.

Key Questions Answered in the Report-

• What is the current revenue generated by the real-world evidence solutions market globally?
• At what rate is the global real-world evidence solutions market demand projected to grow for the next 7-10 years?
• What are the historical market sizes and growth rates of the global real-world evidence solutions market?
• What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
• Which segments in terms of component, application, and end user are expected to create major traction for the service providers in this market?
• What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global real-world evidence solutions market?
• Who are the major players in the global real-world evidence solutions market? What are their specific service offerings in this market?
• What are the recent strategic developments in the global real-world evidence solutions market? What are the impacts of these strategic developments on the market?

Scope of the Report:

Real-World Evidence Solutions Market Assessment -- by Component

• Datasets
• Services (Consulting & Analytics)

Real-World Evidence Solutions Market Assessment -- by Application

• Drug Development & Approvals
• Market Access & Reimbursement/Coverage Decisions
• Post-Market Surveillance

Real-World Evidence Solutions Market Assessment -- by End User

• Pharmaceutical, Biotechnology, and Medical Device Companies
• Payers
• Healthcare Providers

Real-World Evidence Solutions Market Assessment -- by Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Australia
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
• Rest of Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Ecosystem
• 1.3. Currency and Limitations
  • 1.3.1. Currency
  • 1.3.2. Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Data Collection & Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research
• 2.3. Market Assessment
  • 2.3.1. Market Size Estimation
  • 2.3.2. Bottom-Up Approach
  • 2.3.3. Top-Down Approach
  • 2.3.4. Growth Forecast
• 2.4. Assumptions for the Study

3. Executive Summary

• 3.1. Overview
• 3.2. Market Analysis, by Component
• 3.3. Market Analysis, by Application
• 3.4. Market Analysis, by End User
• 3.5. Market Analysis, by Geography
• 3.6. Competitive Analysis

4. Market Insights

• 4.1. Introduction
• 4.2. Global Real-World Evidence Solutions Market: Impact Analysis of Market Drivers (2026-2036)
  • 4.2.1. Increasing Focus on Personalized Healthcare and Value-Based Care
  • 4.2.2. Rising Drug Development Costs and Delays
  • 4.2.3. Growing Regulatory Acceptance of RWE
• 4.3. Global Real-World Evidence Solutions Market: Impact Analysis of Market Restraints (2026-2036)
  • 4.3.1. Data Privacy and Security Concerns
  • 4.3.2. Lack of Standardized Methodologies
• 4.4. Global Real-World Evidence Solutions Market: Impact Analysis of Market Opportunities (2026-2036)
  • 4.4.1. Emerging Economies
  • 4.4.2. Rising Focus on End-to-End RWE Services
• 4.5. Global Real-World Evidence Solutions Market: Impact Analysis of Market Challenges (2026-2036)
  • 4.5.1. Data Quality and Completeness Issues
• 4.6. Global Real-World Evidence Solutions Market: Impact Analysis of Market Trends (2026-2036)
  • 4.6.1. Integration of Artificial Intelligence
  • 4.6.2. Growing Adoption of RWE in Drug Development and Commercialization
• 4.7. Porter's Five Forces Analysis
  • 4.7.1. Threat of New Entrants
  • 4.7.2. Bargaining Power of Suppliers
  • 4.7.3. Bargaining Power of Buyers
  • 4.7.4. Threat of Substitute Products
  • 4.7.5. Competitive Rivalry

5. Global Real-World Evidence Solutions Market, by Component

• 5.1. Introduction
• 5.2. Datasets
  • 5.2.1. Disparate Datasets
    • 5.2.1.1. EMR/EHR/Clinical Data
    • 5.2.1.2. Claims & Billing Data
    • 5.2.1.3. Pharmacy Data
    • 5.2.1.4. Product/Disease Registries Data
    • 5.2.1.5. Genomics Data
    • 5.2.1.6. Other Disparate Datasets
  • 5.2.2. Integrated Datasets
• 5.3. Consulting & Analytics

6. Global Real-World Evidence Solutions Market, by Application

• 6.1. Introduction
• 6.2. Market Access & Reimbursement/Coverage Decisions
• 6.3. Drug Development & Approvals
  • 6.3.1. Oncology
  • 6.3.2. Neurology
  • 6.3.3. Immunology
  • 6.3.4. Cardiovascular Diseases
  • 6.3.5. Other Therapeutic Areas
• 6.4. Post-market Surveillance
• 6.5. Medical Device Development & Approvals
• 6.6. Other Applications

7. Global Real-World Evidence Solutions Market, by End User

• 7.1. Introduction
• 7.2. Pharmaceutical, Biotechnology, and Medical Device Companies
• 7.3. Healthcare Payers
• 7.4. Healthcare Providers
• 7.5. Other End Users

8. Real-World Evidence Solutions Market, by Geography

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. U.S.
  • 8.2.2. Canada
• 8.3. Europe
  • 8.3.1. U.K.
  • 8.3.2. Germany
  • 8.3.3. France
  • 8.3.4. Italy
  • 8.3.5. Spain
  • 8.3.6. Rest of Europe
• 8.4. Asia-Pacific
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Rest of Asia-Pacific
• 8.5. Latin America
• 8.6. Middle East & Africa

9. Competitive Landscape

• 9.1. Introduction
• 9.2. Key Growth Strategies
• 9.3. Competitive Dashboard
• 9.4. Market Share/Ranking by Key Players

10. Company Profiles

• 10.1. IQVIA Holdings Inc.
• 10.2. Icon plc
• 10.3. Thermo Fisher Scientific Inc.
• 10.4. F. Hoffmann-La Roche Ltd
• 10.5. Oracle Corporation
• 10.6. Elevance Health, Inc.
• 10.7. Clinigen Group Plc
• 10.8. Cognizant Technology Solutions Corporation
• 10.9. Revvity, Inc.
• 10.10. SAS Institute Inc.
• 10.11. Parexel International Corporation
• 10.12. Healthverity, Inc.

11. Appendix

• 11.1. Questionnaire
• 11.2. Available Customization